[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% -X%
1 Month: XX% +12%
6 Months: XX% +2%
1 Year: XX% no change
1-Year High: XX% on 2024-10-20
1-Year Low: XX% on 2025-08-26
Most Supportive Themes
- Kesimpta Benefits: (35%) Positive data supporting the benefits of Kesimpta in relapsing multiple sclerosis (RMS) is being shared across multiple social networks.
- Novartis's Innovation and Investment: (20%) Mentions of Novartis's investments in R&D and acquisitions, such as Regulus Therapeutics, are generating positive sentiment.
- Access to Medicines: (15%) Positive sentiment around Novartis's efforts to provide access to medicines, particularly in collaboration with organizations like the UICC.
Most Critical Themes
- US Price Cuts: (10%) Discussions around potential price cuts in the US market, driven by CEO comments and potential tariff impacts, are generating some critical sentiment.
- Patent Revocation: (5%) The revocation of Novartis's patent for Vymada in India is a critical point.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXXXXXX | XX% | XXXXX | X% | XXX | X% |
| TikTok | XXXXXX | XX% | XXXXX | X% | XXX | X% |
| YouTube | XXXXX | X% | XXXXX | X% | XXX | X% |
| X | X% | XX | X% | X | X% | |
| News | X | X% | XXX | X% | X | X% |
| Total | XXXXXXX | XX% | XXXXXX | X% | XXXXX | X% |